EP1635849A1 - Heilmittel zur inneren anwendung; insbesondere gegen krebserkrankungen - Google Patents

Heilmittel zur inneren anwendung; insbesondere gegen krebserkrankungen

Info

Publication number
EP1635849A1
EP1635849A1 EP04733761A EP04733761A EP1635849A1 EP 1635849 A1 EP1635849 A1 EP 1635849A1 EP 04733761 A EP04733761 A EP 04733761A EP 04733761 A EP04733761 A EP 04733761A EP 1635849 A1 EP1635849 A1 EP 1635849A1
Authority
EP
European Patent Office
Prior art keywords
surfactants
polydimethylsiloxane
weight
proportion
medicinal product
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP04733761A
Other languages
German (de)
English (en)
French (fr)
Inventor
Gerd THÖNE
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bauer Wulf Dr
Original Assignee
Bauer Wulf Dr
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bauer Wulf Dr filed Critical Bauer Wulf Dr
Publication of EP1635849A1 publication Critical patent/EP1635849A1/de
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/80—Polymers containing hetero atoms not provided for in groups A61K31/755 - A61K31/795
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Definitions

  • the present invention relates to a remedy for internal use, especially against cancer.
  • This object is achieved by a remedy which has polydimethylsiloxane and surfactants, the proportion of polydimethylsiloxane exceeding the proportion of surfactants.
  • the special feature of the invention is that the effect according to the invention is achieved only by adding surfactants.
  • Mixing the polydimethylsiloxane with surfactants means that the body is given the opportunity to emulsify the siloxane and make it usable. This is achieved by the surfactants breaking up the molecular structure of the polydimethylsiloxane.
  • the proportion of surfactants, based on the weight of the solution, can be significantly lower than the proportion of polydimethylsiloxane.
  • Anionic, amphoteric and nonionic surfactants can be used, the proportion by weight of the anionic surfactants exceeding the proportion by weight of the amphoteric and nonionic.
  • Polydimethylsiloxane is made from raw silicon.
  • Raw silicon is obtained from sand and coal, which is further processed into the desired silicones in a continuous process.
  • Natural gas or crude oil are used to produce methanol (synthesis gas), another starting material for silicone synthesis.
  • Chlorine is obtained by electrolysis of rock salt solutions and is added to the process in the form of HC1.
  • methanol is converted to chloromethane with HC1 (chloromethane synthesis).
  • a mixture of crude silanes (chlorosilane synthesis) is then obtained by reacting chloromethane with silicon. These are separated by distillation, dichlorodimethylsilane (CH3) 2SiC12 then being converted into polydimethylsiloxane by hydrolysis.
  • the remedy is nebulized using suitable nebulization techniques.
  • suitable nebulization techniques Various devices are available for this:
  • Compressed air operated Venturi nozzle nebulizer a) direct nebulization b) with aerosol reservoir c) with positive pressure inhalation 2.
  • Mechanical single-component jet nebulizer a) direct nebulization b) with aerosol reservoir c) with positive pressure inhalation 2.
  • aluminum silicate in particular natural zeolite with a grain size of 10 ⁇ m to 70 ⁇ m, in particular 40 ⁇ m and dolomite powder with a grain size of 2 ⁇ m to 30 ⁇ m, in particular 10 ⁇ m, can also be added. This results in powder that can be administered in capsules.
  • the basic skeleton of the crystal lattice of the zeolite consists primarily of SiÜ4 tetrahedra. It has cavities in which ions, e.g. B. are sodium, potassium and calcium, which can be easily exchanged with themselves and with their substrate environment.
  • This mineral-specific crystal structure (cage structure) of zeolite has the excellent property in living organisms, toxic substances, such as. B. ammonia and other nitrogen compounds, but also heavy metals, to bind (absorb) and excrete via the intestinal metabolism. The extracted toxic substances are exchanged for minerals that the body urgently needs. In this way, the homeostasis of the organism, in particular that of the mineral metabolism, is maintained or restored.
  • the zeolite also has a positive stimulating effect on the entire metabolism and in the growth and healing processes of the organism.
  • zeolite Because of its open molecular structure, zeolite also has the ability to absorb large quantities of liquids. This is advantageous since, despite mixing with the additional components mentioned above, a flowable powder can be formed.
  • the additional components may have the proportions in the end product:
  • Aluminum silicate 50 to 90, in particular 70% by weight,
  • the resulting mixture is a flowable powder and can be processed into a remedy in a variety of ways. It is thus possible to encapsulate the powdery mixture, for example in the form of the widely used gelatin capsules, which dissolve in the digestive tract. In addition, it is readily possible to press tablets from the powdered mixture, which can be taken with or without liquid.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
EP04733761A 2003-05-22 2004-05-19 Heilmittel zur inneren anwendung; insbesondere gegen krebserkrankungen Withdrawn EP1635849A1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10323758A DE10323758A1 (de) 2003-05-22 2003-05-22 Heilmittel zur inneren Anwendung, insbesondere gegen Krebserkrankungen
PCT/DE2004/001048 WO2004105776A1 (de) 2003-05-22 2004-05-19 Heilmittel zur inneren anwendung; insbesondere gegen krebserkrankungen

Publications (1)

Publication Number Publication Date
EP1635849A1 true EP1635849A1 (de) 2006-03-22

Family

ID=33441299

Family Applications (1)

Application Number Title Priority Date Filing Date
EP04733761A Withdrawn EP1635849A1 (de) 2003-05-22 2004-05-19 Heilmittel zur inneren anwendung; insbesondere gegen krebserkrankungen

Country Status (9)

Country Link
US (1) US20070172435A1 (cg-RX-API-DMAC7.html)
EP (1) EP1635849A1 (cg-RX-API-DMAC7.html)
JP (1) JP2006528211A (cg-RX-API-DMAC7.html)
CN (1) CN1795001A (cg-RX-API-DMAC7.html)
AU (1) AU2004243524A1 (cg-RX-API-DMAC7.html)
CA (1) CA2526175A1 (cg-RX-API-DMAC7.html)
DE (1) DE10323758A1 (cg-RX-API-DMAC7.html)
RU (1) RU2005140097A (cg-RX-API-DMAC7.html)
WO (1) WO2004105776A1 (cg-RX-API-DMAC7.html)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10323759A1 (de) * 2003-05-22 2004-12-16 Bauer, Wulf, Dr. Heilmittel zur inneren Anwendung, insbesondere gegen Krebserkrankungen
BE1018537A3 (fr) 2007-09-13 2011-03-01 Basf Se Procede d'exploitation d'une separation en continu d'un produit cible x sous la forme d'un cristallisat finement divise.
DE102007043758A1 (de) 2007-09-13 2008-10-23 Basf Se Verfahren zum Betreiben einer kontinuierlichen Abtrennung eines Zielproduktes X in Form von feinteiligem Kristallisat des Zielproduktes X
DE102007043759A1 (de) 2007-09-13 2008-09-11 Basf Se Verfahren zum Betreiben einer kontinuierlichen Abtrennung eines Zielproduktes X in Form von feinteiligem Kristallisat
DE102007043748A1 (de) 2007-09-13 2008-09-11 Basf Se Verfahren zur kontinuierlichen Abtrennung eines Zielproduktes X in Form von feinteiligem Kristallisat
DE102010030279A1 (de) 2010-06-18 2010-10-28 Basf Se Verfahren der Inbetriebnahme eines Trennverfahrens zur reinigenden Abtrennung von Acrylsäurekristallen aus einer Suspension S ihrer Kristalle in Mutterlauge
US8461383B2 (en) 2009-10-16 2013-06-11 Basf Se Process for starting up a separating process for purifying removal of acrylic acid crystals from a suspension S of crystals thereof in mother liquor
DE102009045767A1 (de) 2009-10-16 2010-08-12 Basf Se Verfahren der Inbetriebnahme eines Trennverfahrens zur reinigenden Abtrennung von Acrylsäurekristallen aus einer Suspension S ihrer Kristalle in Mutterlauge
AU2015354399B2 (en) * 2014-11-24 2020-05-14 Bio-Latem Technologies Pty Limited Methods for the treatment and prevention of asbestos-related diseases
CN104606261B (zh) * 2015-03-05 2018-02-09 潘友长 一种沸石药物组合物及其制备方法和用途
CN105837734A (zh) * 2016-05-09 2016-08-10 上海惠昌化工厂 有机硅改性丙烯酸聚酯钾盐及制备方法和防癌治癌用途

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5310572A (en) * 1987-02-03 1994-05-10 Dow Corning Corporation Process for forming a coated active agent-containing article
US5418220A (en) * 1994-03-08 1995-05-23 Schmidt; Alfred Method for treating constipation using dimethicone
US5587149A (en) * 1995-02-06 1996-12-24 R.P. Scherer Corporation Topical application emulsions
EP0889721B1 (de) * 1996-03-25 2002-04-17 Bauer, Wulf Heilmittel zur äusserlichen anwendung und verwendung einer wässrigen öl-emulsion für ein derartiges heilmittel
US6347408B1 (en) * 1998-11-05 2002-02-19 Allegiance Corporation Powder-free gloves having a coating containing cross-linked polyurethane and silicone and method of making the same
AU3164899A (en) * 1999-04-26 2000-11-10 Tihomir Lelas Device for micronizing materials

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO2004105776A1 *

Also Published As

Publication number Publication date
DE10323758A1 (de) 2004-12-16
AU2004243524A1 (en) 2004-12-09
RU2005140097A (ru) 2006-08-10
CN1795001A (zh) 2006-06-28
WO2004105776A1 (de) 2004-12-09
US20070172435A1 (en) 2007-07-26
CA2526175A1 (en) 2004-12-09
JP2006528211A (ja) 2006-12-14

Similar Documents

Publication Publication Date Title
JP2021191766A (ja) 骨障害、軟骨障害又はその両方の管理又は改善用組成物及び方法
WO2004105776A1 (de) Heilmittel zur inneren anwendung; insbesondere gegen krebserkrankungen
DE19749724A1 (de) Verwendung einer Kombination aus Opioid und alpha-adrenergem Agonisten in Schmerzmitteln
DE10323759A1 (de) Heilmittel zur inneren Anwendung, insbesondere gegen Krebserkrankungen
EP0037488B1 (de) Pharmazeutisches Mittel zur Heilung von entzündlichen und/oder degenerativen und/oder atrophischen Schleimhauterkrankungen
DE2113215A1 (de) Therapeutisches Kompositum
DE2504331A1 (de) Heptaminol-5'-adenosinmonophosphat und dessen therapeutische verwendung
DE69100954T2 (de) Lagerstabile orale Glucosaminsulfat-Dosisformen und Verfahren zu deren Herstellung.
DE1767017A1 (de) Eisenpraeparat
DE2062715C3 (de) Verfahren zur Herstellung von oral applizierbaren Arzneimittelzubereitungen mit protrahierter Wirkstoffabgabe und Arzneimittelzubereitung
JP2006528210A5 (cg-RX-API-DMAC7.html)
EP2897906B1 (en) Process for bio synthesis of nano arsenic trioxide and its use in treatment of diseases including cancers
EP0256353A2 (de) Pharmazeutikum zur Therapie einer schlechten Absorption von Nahrungsmitteln und von Oral einzunehmenden Medikamenten
DE102015002709A1 (de) Neue Verwendung von Acetylsalicylsäure und einem Derivat davon
EP2130545A2 (de) Lösung und Tinktur
RU2836810C1 (ru) Растительные ветеринарные композиции против нематод
DE69901843T2 (de) Eine oder mehrere komponente des perlmuttes einschliesslich bio-aragonit enthaltendes homeopathisches arzneimittel
EP2509613A1 (de) Zusammensetzung zur behandlung von magen- und darmbeschwerden
EP3373911A1 (de) Kombination von calciumsulfat und gummi arabicum
CN106806411A (zh) 治疗或缓解呼吸系统疾病症状的外用药物及其制备方法
RU2407537C1 (ru) Способ лечения и профилактики желудочно-кишечных и легочных заболеваний у молодняка животных и птиц
DE602004002718T2 (de) Pharmazeutische Zusammensetzungen zur Behandlung von Herpes Zoster
DE102023124464A1 (de) Kosmetische oder dermatologische Zubereitung und Verfahren zur Herstellung einer solchen Zubereitung
DE102010026471A1 (de) Verwendung eines Schwefelpräparates zur Herstellung eines Arzneimittels für die Behandlung von asthmatischen Erkrankungen
DE629896C (de) Herstellung von Reaktionsprodukten aus Arsenik und Arsensaeure

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20051222

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PL PT RO SE SI SK TR

DAX Request for extension of the european patent (deleted)
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20091201